← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Symberix, Inc.
Durham, NC
$7,360,599
Total funding
10
Grants
Funding over time
peak $2.5M · FY2014–22$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,360,599 · 10
By mechanism
R44$5,656,406 · 3
R43$1,435,552 · 6
N43$268,641 · 1
Investigators at Symberix, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$999,480
R44 · FY2020 · CA
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$987,570
R44 · FY2019 · CA
Development of a companion diagnostic to identify patients who respond to microbiome-targeting drugs$884,165
R44 · FY2020 · GM
Development of a companion diagnostic to identify patients who respond to microbiome-targeting drugs$846,715
R44 · FY2021 · GM
Developing novel inhibitors of the gut microbiome to modulate drug metabolism$787,689
R44 · FY2021 · TR
Developing novel inhibitors of the gut microbiome to modulate drug metabolism$625,834
R44 · FY2020 · TR
Small molecule drugs targeting gut dysbiosis to manage inflammatory bowel disease$304,553
R43 · FY2022 · DK
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$300,000
R44 · FY2018 · CA
IGF::OT::IGF SBIR PHASE I, TOPIC 351: IMPROVING TARGETED CANCER THERAPIES BY MODULATING THE INTESTINAL MICROBIOME$268,641
N43 · FY2016 · CA
Therapeutic Adjunct to Improve Immunosuppression Outcomes Following Organ Transplantation$238,047
R43 · FY2018 · DK
Modulation of gut dysbiosis with Enterobacteriaceae-targeted antiproliferative agents to treat inflammatory bowel disease$231,302
R43 · FY2019 · DK
Improving chemotherapy outcomes with proprietary molecules targeting the human mi$225,000
R43 · FY2014 · CA
Developing novel inhibitors of the gut microbiome to modulate drug metabolism$224,953
R44 · FY2019 · TR
The Benchtop Symbiome: developing an integrated mammalian-microbial assay platform to accelerate microbiome-targeted drug discovery$220,944
R43 · FY2018 · GM
Microbiome Targeted Drugs to Improve NSAID Outcomes$215,706
R43 · FY2015 · DK